FUNDAMENTALS · Fundamentals · JP Healthcare

Nippon Shinyaku (4516) Fundamentals 2026 — P/E 9.1x, Revenue Analysis | SniperIQ

Nippon Shinyaku (4516) is a JP-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥270.9B, trading at ¥4019.00 on the JPX. This SniperIQ fundamentals page covers Nippon Shinyaku's valuation (P/E 9.1x, P/B 0.9x), profitability (net margin 17.4%), revenue (¥170.8B in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap¥270.9B
P/E (TTM)9.1x
Net Margin17.4%
Revenue (FY26)¥170.8B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Nippon Shinyaku's market cap?

Nippon Shinyaku (4516) has a market capitalization of approximately ¥270.9B, trading at ¥4019.00 on the JPX. Market cap moves with the live share price.

What is Nippon Shinyaku's P/E ratio?

Nippon Shinyaku's trailing twelve-month P/E ratio is 9.1x, with a price-to-book (P/B) of 0.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Nippon Shinyaku?

Nippon Shinyaku runs a net profit margin of 17.4%, a gross margin of 66.4%, and an operating margin of 19.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Nippon Shinyaku generate?

Nippon Shinyaku reported revenue of ¥170.8B for fiscal year 2026, with net income of ¥29.7B and earnings per share (EPS) of 441.25. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Nippon Shinyaku pay a dividend?

Nippon Shinyaku offers a trailing dividend yield of about 3.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is Nippon Shinyaku financially healthy?

Nippon Shinyaku carries a debt-to-equity ratio of 0.01x and a current ratio of 4.35x, with a market beta of -0.31. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Nippon Shinyaku a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Nippon Shinyaku (4516) the key facts are: market cap ¥270.9B, P/E 9.1x, revenue ¥170.8B, 52-week range 3067-6529. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Nippon Shinyaku's full fundamentals live

Get Nippon Shinyaku's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: SillaJen (215600) fundamentals · Humedix (200670) fundamentals · Genomictree (228760) fundamentals · Sai Life Sciences (SAILIFE) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons